Cavtat-Dubrovnik, Croatia
More info
Innate Pharma and Novo Nordisk announce strategic partnership to research and develop drugs targeting natural killer cells.
Dr. Squiban, 53, joined Innate Pharma after eight years at Transgene (1997-2005), a French company dedicated to the discovery and development of therapeutic vaccines and gene therapy products, as Director of Medical Affairs Europe and then as Vice President, Medical and Regulatory Affairs.
This certification marks a new milestone in the maturation of the company, obtained at a time when Innate Pharma is significantly building up its team, enlarging its portfolio of compounds and working on various new industrial partnerships.
Innate Pharma S.A., a biopharmaceutical company specialized in cancer immuno- therapeutics, today announced the achievement of the first milestone in their collaboration with Novo Nordisk A/S in Denmark.